 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Onyx Pharmaceuticals, Inc.
 |
Onyx Pharmaceuticals, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Onyx shares fall on changed pact, Q2 results Aug 08 2001 07:06 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
ONYX Pharmaceuticals' cancer drug could turn out to be a real gem. The firm's lead drug candidate, ONYX-015, is genetically engineered to kill head and neck cancer cells resistant to such treatments as chemotherapy and radiation while leaving normal cells intact. ONYX-015 is in latter-stage clinical trials, conducted by partner Warner-Lambert, now part of Pfizer. The drug candidate is also in development to treat pancreatic, ovarian, colorectal, and lung cancers. ONYX has also partnered with Pfizer to develop enzymes that inhibit inflammatory diseases and regulate cell cycles to prevent cancer. With partner Bayer, the company is developing a kinase inhibitor that blocks tumor cell growth.
COMPETITION |
 |
Aventis (AVE)
Introgen Therapeutics, Inc. (INGN)
OSI Pharmaceuticals, Inc. (OSIP)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 24.20
1-Yr. Sales Growth: 82.0%
Employees: 135
Revenue per employee: $179,259.26
KEY PEOPLE |
 |
Hollings C. Renton
CEO
CONTACT INFO |
 |
3031 Research Dr.
Richmond, CA 94806
US
Phone: 510-222-9700
Fax: 510-222-9758
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |